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Abstract There is a growing body of evidence implicating
inflammatory cytokines and brain-derived neurotropic factor
(BDNF) in the generation of migraine pain. No previous
study evaluated BNDF levels during migraine attacks and
there are conflicting results regarding tumor necrosis factor-
alpha (TNF-alpha) serum levels. This study compared serum
levels of TNF-alpha, soluble TNF receptors 1 and 2 (sTNF-
R1 and sTNF-R2), and BDNF during migraine attacks and in
headache-free periods. Nine patients with episodic migraine
were clinically evaluated during a migraine attack and in a
headache-free period. Blood sample of each patient in both
occasions was collected and all serum was submitted to TNF-
alpha, sTNF-R1, sTNF-R2, and BDNF determination by
ELISA. There was no significant difference in the serum
levels of TNF-alpha, sTNF-R1 and sTNF-R2 in migraine
attack period and headache-free period. BDNF serum levels
were significantly higher during migraine attack than in pain-
free period. This is the first report showing that BDNF serum
levels increase during migraine attack. This reinforces the
view that BDNF may be implicated in the physiopathology
of migraine.
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Introduction
Migraine is a very common neurologic disorder [1]. The
mechanisms involved in the generation of migraine attack
are probably multifactorial and are not fully understood [2].
It has been proposed that neurogenic inflammation causes
pain during migraine attack. The neurogenic inflammation
is generated by the release of neuropeptides such as cal-
citonin gene-related peptide (CGRP) from trigeminal neu-
rons terminals and leads to inflammation with the release of
cytokines such as interleukin-6 (Il-6) and tumor necrosis
factor-alpha (TNF-a) [2]. Some studies demonstrated ele-
vated levels of these cytokines in jugular vein during acute
migraine attacks, however, there were discrepant results
with respect to the determination of serum levels of cyto-
kines in migraine patients [3–6].
Brain-derived neurotropic factor (BDNF) is a neurotro-
phin that has been implicated in the generation and mod-
ulation of pain [7]. Some studies have found that BDNF
levels are altered in migraine patients when compared to
controls [8]. No previous study evaluated BDNF serum
levels during migraine attacks. Therefore, it is unknown
whether there is any change in the serum level of BDNF
during migraine attacks.
The aim of this study was to investigate the levels of
TNF-a, soluble TNF receptors 1 and 2 (sTNF-R1 and
sTNF-R2), and BDNF during migraine attack and in




Nine patients with established diagnosis of episodic
migraine without aura were included in this study. The
patients were evaluated at the Hospital Madre Teresa, Belo
Horizonte, Brazil. The diagnosis of migraine was done by a
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headache specialist according to the International Head-
ache Criteria [9]. All patients signed informed consent
form before inclusion in the study and this study was
approved by the local ethics research committee. Age,
gender, and time of migraine attacks history were recorded.
The impact of migraine was evaluated with migraine dis-
ability assessment (MIDAS) and headache impact test
(HIT) [10].
The patients were evaluated twice. The first evaluation
was during a migraine attack when the patients sought
medical attention. At this time the headache intensity was
also evaluated by the visual analogue scale (VAS). The
second evaluation was performed 1 week later if the
patient reported to be completely pain free in the last 72 h.
In both evaluations blood samples were collected for the
determination of serum markers.
Measurement of TNF-a, sTNF-R1, sTNF-R2
and BDNF
Blood was aseptically collected. Serum was separated
within 30 min and the supernatant was stored at -70C
until required. For analysis, samples were thawed. The
concentration of TNF-a, sTNF-R1, sTNF-R2 and BDNF in
serum of migraine patients with and without pain was
assessed by using sandwich ELISA kits (Highly Sensitive
R&D Systems, for TNF-a and Duo Set R&D Systems
Minneapolis, MN, USA, for sTNF-R1, sTNF-R2 and
BDNF). The detection limits for these assays were 0.5 pg/
ml for TNF-a and 5.0 pg/ml for sTNF-R1, sTNF-R2 and
BDNF.
Statistical analysis
Wilcoxon signed-rank test was used for comparison of
TNF-a, sTNF-R1, sTNF-R2, and BDNF concentrations
from the patients during the migraine attack and in the
pain-free period. Spearman correlation test was used to
evaluate correlation between age, time of migraine,
MIDAS, HIT, and VAS with serum TNF-a, sTNF-R1,
sTNF-R2, and BDNF concentrations. All the calculations
were performed using GraphPad Prism version 4.00 for
Windows software (GraphPad Software Inc., San Diego,
CA, USA). The level of significance was set at P \ 0.05.
Results
Eight of the nine patients were women. The mean age was
23.8 ± 2.8 mean ± SD MIDAS and HIT scores were
39.5 ± 44.8 and 63.3 ± 5.7, respectively. The intensity of
pain during migraine attack period ranged from 5 to 10, the
mean being 8.4 ± 1.7.
The comparison of TNF-a, sTNF-R1, sTNF-R2 serum
levels during migraine attack and during pain-free period
are shown in Fig. 1. There was no significant difference in
TNF-a (sum of signed ranks (W) -6.0), sTNF-R1 (sum of
signed ranks (W) 15.0), sTNF-R2 (sum of signed ranks (W)
-17.0) levels between these two periods (P [ 0.05).
The comparison of BDNF serum levels during migraine
attack and during migraine-free period is shown in Fig. 1.
BDNF serum levels were significantly increased during
migraine attack period (sum of signed ranks (W) 43.0;
P = 0.008).
Age, length of disease, MIDAS, HIT and VAS scores
did not correlate with TNF-a, sTNF-R1 and sTNF-R2
levels during migraine attack or in the headache-free per-
iod. Serum levels of BDNF were inversely correlated with
the headache (r = 0.6325, P = 0.043).
Discussion
Cytokines are pain mediators and it is believed that they
are implicated in neurovascular inflammation resulting in
migraine pain [2]. In this study, we found no significant
differences in the serum levels of TNF-a, sTNF-R1, and
sTNF-R2 during migraine attack and attack-free period and
no correlation between these cytokines and clinical
parameters.
Other studies have also investigated TNF-a level during
and outside migraine attacks with contradictory results.
While some studies found no difference in TNF-a serum
levels [3, 4], others described increased levels of TNF-a
during migraine attack [5]. Regarding that TNF-a is an
unstable molecule with a reduced half-life, several authors
assess its soluble receptors as an index of TNF-a activity
[11]. Empl et al. found decreased levels of sTNF-R1 during
migraine attack, suggesting that this would result in less
buffer capacity for locally released hyperalgesic TNF-a
[12]. In contrast, we found no difference in the serum
levels of sTNF-R1 and sTNF-R2 levels during migraine
attacks, undermining the view of increased TNF-a activity
during headache period. The same finding was previously
reported in children with migraine attack [12]. Future
studies are needed to better establish the role of TNF-a in
the generation of migraine attack.
There is little evidence that BDNF levels are altered in
migraine patients and that BDNF gene polymorphisms are
related with genetic susceptibility to migraine [8, 13]. In
this study, there was an increased serum level of BDNF
during migraine attack when compared to headache-free
period. Besides its neurotrophic function, BDNF is a pain
modulator acting in the efficiency of glutamatergic and
GABAergic/glycinergic synapses [7]. Also, BDNF is in
involved in the pathogenesis of migraine comorbidities
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such as epilepsy and depression [14]. The precise role of
BDNF in epilepsy is not fully understood but BDNF
infusion has been shown to induce seizures and scavenging
BDNF in vitro appears to reduce kindling development
[14]. Considering that an imbalance between excitatory
glutamate-mediated transmission and GABA-mediated
inhibition has been postulated in migraine pathogenesis
and that BDNF has been shown to modify excitability, it is
possible that increased BDNF concentration may partici-
pate in the generation of migraine attack. Moreover, BDNF
was recently shown to intermediate an increase of CGRP
P2X3 receptor synthesis. The increase in the expression of
P2X3 receptor would enhance the effect of released CGRP
in triggering neurogenic inflammation [15]. Thus, BDNF is
a possible mediator of trigeminal nociceptive plasticity.
This study has limitations. The number of patients is too
small to be able to draw definite conclusions. There is no
age matched control group. We did not the phase of
menstrual cycle the female patients were when the blood
was collected. These results need to be confirmed in future
studies with a more conspicuous number of patients and
with a more controlled definition of the time of blood
sampling both during the ictal and interictal period.
To the best of our knowledge, this is the first report to
show that BDNF level is increased during migraine attack
and that it is inversely related with headache intensity. The
relevance of BDNF in migraine is possibly related with
CGRP action [15]. Currently, there are two CGRP antag-
onists being tested for migraine attacks in phase II and
phase III studies, olcegepant and telcagepant [2, 16, 17]. It
is extremely important to investigate if neurotropic factors
production is influenced by the use of these new drugs.
Also, future studies should evaluate these molecular
mediators in different types of migraine, the effects of
prophylactic therapy, and the impact of migraine comor-
bidities such as depression and anxiety on the levels of
these mediators. A better knowledge of the relevance of
molecular mediators of migraine as well as their central
and peripheral actions may provide clues to the develop-
ment of future new drugs directed to different targets of the
migraine pathophysiologic process.
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Fig. 1 TNF, sTNF-R1, and
sTNF-R2 serum levels in
patients during migraine attacks
and in headache-free periods
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